The scene
The product page looks stronger. The sales deck is being updated to match. The investor deck uses the same sentence.
Public copy is wet concrete. At first, it looks easy to smooth over. Then it hardens into the sentence investors quote back, distributors repeat, customers remember, and sales teams build from.
The wrong frame
The weak question is, 'Does the copy sound strong enough?' The stronger question is, 'Which public sentences are ready to become part of the company's external story?'
The risk is not one imperfect sentence. The risk is months of investor, customer, distributor, website, and sales language built on a claim nobody separated from the assumptions underneath it.
Build one claim-readiness map
| Row | Question to answer |
|---|---|
| Public claim | What exact sentence are we about to publish? |
| Source support | What public source, internal record, or reviewed evidence supports it? |
| Public vs. internal knowledge | What is source-supported in public records, and what only your team knows? |
| Open claims | What claims still need review before appearing in customer, investor, website, or sales material? |
| Safer wording | What narrower version still helps the reader understand the product? |
| Owner | Who needs to review this before external use? |
The founder-level move
Strong public language is not the loudest version of the truth. It is the version your company can keep using after customers, investors, partners, and reviewers start asking follow-up questions.
A mature team does not weaken every claim. It separates what is ready from what is still being earned.
Source ledger
What it can tell you
FDA describes United States device market-entry steps and broad regulatory-control context, including labeling and misbranding concepts.
What it cannot decide
Specific website, deck, sales, investor, or partner language for a company.
What it can tell you
FDA describes misleading labeling and advertising considerations.
What it cannot decide
Whether a specific public claim is misleading, compliant, cleared, approved, safe, or effective.
What it can tell you
FDA guidance discusses medical-product communications and fact-specific consistency with FDA-required labeling.
What it cannot decide
Whether a specific website sentence, sales claim, investor claim, or partner statement is consistent with labeling.
What it can tell you
FDA describes intended use and indications for use as important concepts in determining whether a product is a medical device.
What it cannot decide
A specific product's classification, intended-use boundary, indication, clearance, approval, safety, or effectiveness.
Frequently asked questions
Is this a legal review of website copy?
No. It is a founder preparation map. The company, counsel, qualified regulatory reviewer, quality owner, or other appropriate reviewer must decide final public wording.
Why include FDA guidance references at the end?
They are boundary references. They support the need to treat intended use, labeling, misleading communication, and product-communication questions carefully, but they do not decide a specific sentence.
What should I do before publishing a product page?
Map each important public claim to source support, public versus internal knowledge, open review questions, safer wording, and the owner who needs to review it before external use.
Need public language ready before the page becomes permanent?
Request the Market-Ready Sales & Support Pack overview to see how one product page, one buyer, and one review team become a claim-boundary workflow.